Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Vaccinations

Vaccinations

Immune Response Against Viral Pathogens

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Identification of alterations of immunometabolism associated with Pompe disease.

Cellular and molecular life sciences : CMLS·2026

Same author

Overcoming barriers to commercially pre-viable gene and cell therapies for rare and ultra-rare diseases.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Same author

AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain.

Nature communications·2025

Same author

Repeated dosing of AAV-mediated liver gene therapy in juvenile rat and mouse models of Crigler-Najjar syndrome type I.

Molecular therapy. Methods & clinical development·2024

Same author

Treatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapy.

Molecular metabolism·2024

Same author

Liver-Directed Adeno-Associated Virus-Mediated Gene Therapy for Mucopolysaccharidosis Type VI.

NEJM evidence·2024

Search research articles

Related Experiment Video

Updated: Apr 26, 2026

A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay

A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay

Published on: December 7, 2021

Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions.

Etiena Basner-Tschakarjan¹, Federico Mingozzi²

¹Department of Hematology, The Children's Hospital of Philadelphia , Philadelphia, PA , USA.

Frontiers in Immunology

|August 8, 2014

Summary

Adeno-associated virus (AAV) vectors are effective for gene therapy but can trigger immune responses. Understanding cytotoxic T cell reactions to AAV capsids is crucial for safe and effective gene transfer.

Keywords:

AAV vectors T cell responses gene therapy immune modulation immunogenicity

More Related Videos

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Published on: January 29, 2019

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors

Published on: April 5, 2024

Related Experiment Videos

Last Updated: Apr 26, 2026

A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay

A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay

Published on: December 7, 2021

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Published on: January 29, 2019

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors

Published on: April 5, 2024

Area of Science:

Gene Therapy
Immunology
Virology

Background:

Adeno-associated virus (AAV) vectors are leading platforms for in vivo gene delivery, with recent market approvals.
Clinical applications highlight the host immune system, particularly cytotoxic T cell responses against the AAV capsid, as a significant barrier to gene transfer efficacy.
Despite advances, critical questions remain regarding AAV vector immunogenicity and its impact on gene therapy outcomes.

Purpose of the Study:

To review the challenges posed by cytotoxic T cell responses to AAV vectors in human gene therapy.
To explore emerging concepts in AAV vector immunogenicity, including dose-dependency, innate immunity, and T cell crosstalk.
To identify unanswered questions and future research directions for optimizing AAV-based gene therapy safety and efficacy.

Main Methods:

Review of current literature on AAV vector immunology and clinical trial data.
Analysis of cytotoxic T cell responses directed against the AAV capsid in human studies.
Discussion of preclinical findings on innate immunity and T cell interactions.

Main Results:

Cytotoxic T cell responses against the AAV capsid are a key obstacle in clinical gene therapy.
Emerging concepts include the role of capsid dose, innate immunity, and regulatory/effector T cell balance.
Significant knowledge gaps persist regarding T cell activation kinetics, individual variability in immune response, and safety of immune-blocking strategies.

Conclusions:

Further research into AAV vector immunogenicity is essential for developing safe and effective gene therapies.
Addressing the complexities of host immune responses, particularly T cell reactions, is critical for advancing AAV-based treatments.
Novel preclinical models and clinical studies are needed to resolve current uncertainties and guide future therapeutic strategies.